This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    precesto
Previous Study | Return to List | Next Study

Study Assessing Efficacy and Safety of NFL-101 on Reduction of Reinforcing Properties of Cigarettes (PRECESTO) (PRECESTO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT06091826
Recruitment Status : Completed
First Posted : October 19, 2023
Last Update Posted : October 19, 2023
Sponsor:
Information provided by (Responsible Party):
Yves Donazzolo, NFL Biosciences SAS

Brief Summary:

PRECESTO is a randomized, double-blind, cross-over trial on 34 smokers who do not want to stop smoking and get high satisfaction from smoking.

The primary objective is to assess efficacy of NFL-101 in reducing the positive reinforcing properties of cigarettes compared to placebo measured by the modified Cigarette Evaluation Questionnaire (mCEQ) "Smoking Satisfaction" (items 1, 2, and 12) subscale.


Condition or disease Intervention/treatment Phase
Smoking Cessation Nicotine Dependence Drug: NFL-101 Drug: Placebo Phase 2

Detailed Description:

PRECESTO is a monocentric, placebo-controlled, randomized and double-blind Phase 2a exploratory study, with a crossover covering two periods of 28 days each, including 34 smokers who do not want to quit and have high smoking satisfaction. Each participant is his or her own control and receives, on a random and alternating basis, either NFL-101 or the placebo at the start of each of the two periods. At the end of the study, all the participants received one dose of NFL-101 and one dose of the placebo. For each participant, the order in which NFL-101 and the placebo are administered is kept secret. For each period, the participants receive the treatments on day 1 (D1) then answer, with complete independence, the modified Cigarette Evaluation Questionnaire (mCEQ) on days 4 (D4), 7 (D7), 14 (D14), 21 (D21) and 28 (D28).

The objective is to assess the safety and efficacy of NFL-101 as a pretreatment for smoking cessation, NFL-101 beeing administered a few days or weeks before a quit attempt while smokers are asked to smoke ad libitum (meaning to continue either to try to smoke the same amount or to smoke freely). It is indeed recognized that reducing satisfaction from smoking before a quit attempt begins to undermine the learned association between smoking and reward and thus promotes the success of these attempts.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 34 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase II Study Assessing Efficacy and Safety of NFL-101 on Reduction of Reinforcing Properties of Cigarettes (PRECESTO Trial)
Actual Study Start Date : February 21, 2023
Actual Primary Completion Date : September 15, 2023
Actual Study Completion Date : September 30, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Smoking

Arm Intervention/treatment
Experimental: NFL-101
100 μg per subcutaneous injection (in each arm), two injections at day 1
Drug: NFL-101
Subcutaneous injections
Other Name: Tobacco leaf extract

Placebo Comparator: Placebo
Water for Injection (WFI), two injections at day 1
Drug: Placebo
Subcutaneous injections
Other Name: Water for injection




Primary Outcome Measures :
  1. Change of smoking satisfaction [ Time Frame: at Day 4 ]
    Success in achieving a 1 point reduction in the mCEQ "Smoking Satisfaction" subscale


Secondary Outcome Measures :
  1. Change of smoking satisfaction [ Time Frame: at Day 7, at Day 14, at Day 21 and at Day 28 ]
    Success in achieving a 1 point reduction in mCEQ "Smoking Satisfaction" subscale

  2. Change in psychological reward, aversion, enjoyment of respiratory tract sensation and craving [ Time Frame: at Day 4, at Day 7, at Day 14, at Day 21 and at Day 28 ]
    Success in achieving a 1 point reduction in mCEQ "Psychological Reward"; "Aversion"; "Enjoyment of Respiratory Tract Sensations"; and "Craving Reduction" subcales

  3. "Have you found your urges to smoke stronger or weaker than usual in the last 24 hours?" [ Time Frame: at Day 4, at Day 7, at Day 14, at Day 21 and at Day 28 ]
    With response options of "much stronger," "slightly stronger," "same as before," "slightly weaker," and "much weaker"

  4. "Have you found cigarettes more or less enjoyable than usual in the last 24 hours?" [ Time Frame: at Day 4, at Day 7, at Day 14, at Day 21 and at Day 28 ]
    With response options of "much more enjoyable," "slightly more enjoyable," "same as before," "slightly less enjoyable," and "much less enjoyable"

  5. Preference question : "Is there one of the two administrations that made you want to quit smoking or reduce your cigarette consumption more than the other?" [ Time Frame: at EOS visit ]
    With response options of administration 1, administration 2, I dont know, imponderable factors (for example covid, death of a relative, job loss, etc.) do not allow me to answer



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Equipped with a web connection via a computer or tablet;
  • Subject currently smoking at least 10 cigarettes per day;
  • Exhaled CO ≥ 9 ppm;
  • Subject with a mCEQ Satisfaction subscale score ≥ 4
  • Subject not wanting to stop smoking (MTSS score ≤ 2)
  • Subject not under tobacco cessation therapy since at least 30 days;
  • Considered as healthy for the study after a comprehensive clinical assessment (detailed medical history and complete physical examination);
  • For women of childbearing potential: commitment to consistently and correctly use of a highly effective contraceptive measure: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner or sexual abstinence for the duration of the trial;
  • Females of non-childbearing potential: either surgically sterilized or at least 1 year postmenopausal (amenorrhea duration at least 12 months);
  • Negative pregnancy test at screening visit;
  • Laboratory parameters within the normal range of the laboratory (hematological, blood chemistry tests). Individual values out of the normal range can be accepted if judged clinically non relevant by the investigator;
  • Negative prick test at screening visit for the whole study product (extract of Tobacco leaf and NaCL), and positive for histamine;
  • Covered by Health Insurance System and / or in compliance with the recommendations of National Law in force relating to biomedical research;
  • Subject having signed the informed consent agreement.

Exclusion Criteria:

  • Pregnancy and breastfeeding;
  • Concomitant participation to another clinical trial;
  • Concomitant active infectious diseases;
  • Suicidal or depressive state
  • Positive results of screening for drugs of abuse
  • History or presence of drug or alcohol abuse (alcohol consumption > 40 grams / day);
  • Subject who would receive more than 4500 euros as indemnities for his participation in biomedical research within the 12 last months, including the indemnities for the present study (for subjects in France only);
  • Subject who, in the judgment of the investigator, is likely to be non-compliant or uncooperative during the study, or unable to cooperate because of a language problem, poor mental development.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06091826


Locations
Layout table for location information
France
Eurofins Optimed
Gières, Isère, France, 38610
Sponsors and Collaborators
NFL Biosciences SAS
Investigators
Layout table for investigator information
Principal Investigator: Yves Donazzolo, MD Eurofins Optimed
Layout table for additonal information
Responsible Party: Yves Donazzolo, MD Eurofins Optimed, NFL Biosciences SAS
ClinicalTrials.gov Identifier: NCT06091826    
Other Study ID Numbers: v1.2
First Posted: October 19, 2023    Key Record Dates
Last Update Posted: October 19, 2023
Last Verified: October 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Tobacco Use Disorder
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders